Skip to main content

Table 3 Predictors of complete response within 7 days of 111 patients with CTXNS-En and CTXS-En bacteremia

From: Clinical and microbiologic characteristics of cefotaxime-non-susceptible Enterobacteriaceae bacteremia: a case control study

Characteristics

Univariate analysis

Multivariate analysis

HR (95% CI)

P-value

HR (95% CI)

P-value

Age

1.01 (0.99–1.02)

0.26

  

Male

1.09 (0.70–1.70)

0.70

  

Nosocomial or healthcare-associated bacteremia

0.85 (0.48–1.51)

0.58

  

Charlson index

0.94 (0.85–1.03)

0.20

0.98 (0.89–0.96)

0.74

Hematological malignancy

1.03 (0.53–2.00)

0.93

  

Solid malignancy

0.95 (0.60–1.49)

0.82

  

Transplantation

0.65 (0.33–1.30)

0.23

  

Hemodialysis

0.43 (0.16–1.19)

0.10

  

Diabetes

1.07 (0.65–1.76)

0.79

  

Cardiac disease

0.86 (0.54–1.37)

0.52

  

Chronic lung disease

0.99 (0.56–1.73)

0.96

  

Liver disease

0.69 (0.40–1.19)

0.18

  

Pancreatobilliary disease

0.93 (0.55–1.60)

0.81

  

Chronic kidney disease

0.95 (0.60–1.50)

0.83

  

Connective tissue disease

0.87 (0.42–1.81)

0.72

  

Intravascular catheter

0.60 (0.39–0.93)

0.02

  

Urinary catheter

0.69 (0.42–1.13)

0.14

  

Mechanical ventilation

0.50 (0.20–1.24)

0.13

  

Other artificial devices

0.74 (0.46–1.17)

0.20

  

Use of all immunosuppressive therapy within 30 days

0.90 (0.58–1.39)

0.64

  

Neutropenia

0.88 (0.47–1.66)

0.70

  

Previous surgery within 30 days

0.69 (0.37–1.27)

0.23

  

Invasive procedure within 30 days

0.63 (0.39–1.04)

0.07

  

Source of infection

 Urinary tract infection

1.17 (0.71–1.94)

0.54

  

 Intraabdominal infection

0.72 (0.42–1.23)

0.23

  

 Pneumonia

0.74 (0.23–2.36)

0.62

  

 Primary bacteremia

0.85 (0.53–1.36)

0.50

  

 SOFA score

0.86 (0.79–0.94)

<0.01

0.88 (0.80–0.96)

<0.01

Empirical therapy

 Carbapenems

0.41 (0.22–0.75)

<0.01

  

 Third-generation cephalosporinsa

2.54 (1.56–4.14)

<0.01

2.13 (1.30–3.50)

<0.01

 Other cephems

1.32 (0.83–2.10)

0.25

  

 β-lactam/β-lactamase inhibitors

0.66 (0.39–1.11)

0.12

  

 Appropriate empirical therapy

1.43 (0.79–2.58)

0.24

  

 CTXNS-En bacteremia

0.64 (0.39–1.03)

0.07

0.73 (0.45–1.19)

0.20

  1. Data are presented as nos. (%) or medians (interquartile ranges)
  2. One patient with CTXNS-En bacteremia and 2 patients with CTXS-En bacteremia were excluded from the analysis because they died before the achievement of complete response at 30 days
  3. All variables with p-values less than 0.05 in the univariate analyses were included in the multivariate analysis. Stepwise logistic regression analysis was performed using forward selection and the likelihood ratio. The Charlson index, SOFA score and CTXNS-En bacteremia were forced into the models
  4. MDR multidrug-resistant, HR hazard ratio, CI confidence interval
  5. aPatients who received third-generation cephalosporin as empirical therapy had lower SOFA scores compared with patients who received other empirical therapies (median = 2 [range: 0–9] and median = 3 [range: 0–21], respectively; p < 0.01)